ADC Therapeutics (ADCT) EBITDA (2020 - 2026)
ADC Therapeutics' (ADCT) quarterly EBITDA came in at -$25.4 million in Q2 2026, up 42.43% year-over-year from -$17.8 million in Q2 2025, and down 0.67% quarter-over-quarter from -$25.2 million in Q1 2026.
Powered by 
Analysis
ADC Therapeutics (ADCT) EBITDA (2020 - 2026) Analysis & Trends
ADC Therapeutics has disclosed EBITDA across 7 years of filings, most recently posting -$25.4 million for Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 3.51 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -10.39 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 1.29 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 493.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -815.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -644.50 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -1.55 Mn |
| 10 | ADC Therapeutics | 172.04 Mn | -47.07 Mn | 17.14 Mn | -25.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -25.41 Mn |
| Mar 31, 2026 | -25.25 Mn |
| Sep 30, 2025 | -30.97 Mn |
| Jun 30, 2025 | -44.15 Mn |
| Mar 31, 2025 | -28.46 Mn |
| Sep 30, 2024 | -35.56 Mn |
| Jun 30, 2024 | -29.04 Mn |
| Mar 31, 2024 | -33.61 Mn |
| Sep 30, 2023 | -36.15 Mn |
| Jun 30, 2023 | -39.65 Mn |
| Mar 31, 2023 | -51.57 Mn |
| Sep 30, 2022 | -3.11 Mn |
| Jun 30, 2022 | -69.41 Mn |
| Mar 31, 2022 | -40.36 Mn |
| Sep 30, 2021 | -57.79 Mn |
| Jun 30, 2021 | -70.48 Mn |
| Mar 31, 2021 | -70.67 Mn |
| Sep 30, 2020 | -52.43 Mn |
| Jun 30, 2020 | -44.95 Mn |
| Mar 31, 2020 | -43.89 Mn |